Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
US6592872B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 15, 1997 |
| Grant date | Jul 15, 2003 |
| Priority date | — |
| Expiry date | Sep 15, 2017 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/825
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary, cytotoxic T lymphocyte vaccine comprising an anthrax protective antigen and a full length protein antigen bound to a nontoxic anthrax protective antigen binding protein comprising at least about the first 250 amino acid residues of the lethal factor of Bacillus anthracis and less than all of the amino acid residues of the lethal factor. The present invention also provides a method of immunizing a mammal against an antigen using the vaccine, and a method of inducing antigen-presenting mammalian cells to present specific antigens via the MHC class I processing pathway.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.